These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 21272677)
1. Administration of adenovirus encoding anti-CD20 antibody gene induces B-cell deletion and alleviates lupus in the BWF1 mouse model. Wang C; Wang M; Liu Y; Zeng P Int Immunopharmacol; 2011 Jun; 11(6):693-7. PubMed ID: 21272677 [TBL] [Abstract][Full Text] [Related]
2. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540 [TBL] [Abstract][Full Text] [Related]
3. A novel pseudovirus encoding Diphtheriatoxin A fragment eliminates autoantibody-producing B cells and inhibits lupus in the BWF1 mouse model. Tan H; Yang X; Cui S; Yang Z Immunol Lett; 2009 Sep; 126(1-2):43-7. PubMed ID: 19660498 [TBL] [Abstract][Full Text] [Related]
4. Treatment of SLE with anti-CD20 monoclonal antibody. Looney RJ; Anolik J; Sanz I Curr Dir Autoimmun; 2005; 8():193-205. PubMed ID: 15564722 [TBL] [Abstract][Full Text] [Related]
5. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943 [TBL] [Abstract][Full Text] [Related]
6. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice. Wofsy D J Immunol; 1986 Jun; 136(12):4554-60. PubMed ID: 3086436 [TBL] [Abstract][Full Text] [Related]
7. Generation of adenovirus-mediated anti-CD20 antibody and its effect on B-cell deletion in mice and nonhuman primate cynomolgus monkey. Chen J; Su C; Lu Q; Shi W; Zhang Q; Wang X; Long J; Yang Q; Li L; Jia X; Wang J; Da W; Liu X; Wu M; Qian Q Mol Cancer Ther; 2008 Jun; 7(6):1562-8. PubMed ID: 18524844 [TBL] [Abstract][Full Text] [Related]
8. Blockade of TLR9 signaling in B cells impaired anti-dsDNA antibody production in mice induced by activated syngenic lymphocyte-derived DNA immunization. Chen M; Zhang W; Xu W; Zhang F; Xiong S Mol Immunol; 2011 Jul; 48(12-13):1532-9. PubMed ID: 21592581 [TBL] [Abstract][Full Text] [Related]
9. Transgenic overexpression of anti-double-stranded DNA autoantibody and activation of Toll-like receptor 4 in mice induce severe systemic lupus erythematosus syndromes. Lee TP; Tang SJ; Wu MF; Song YC; Yu CL; Sun KH J Autoimmun; 2010 Dec; 35(4):358-67. PubMed ID: 20833510 [TBL] [Abstract][Full Text] [Related]
10. [Rituximab in systemic lupus erythematosus. Part I. Theoretical basis]. Kardynał A; Rudnicka L Pol Merkur Lekarski; 2010 Aug; 29(170):131-4. PubMed ID: 20842829 [TBL] [Abstract][Full Text] [Related]
11. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases]. Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605 [TBL] [Abstract][Full Text] [Related]
13. Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus. Wen X; Zhang D; Kikuchi Y; Jiang Y; Nakamura K; Xiu Y; Tsurui H; Takahashi K; Abe M; Ohtsuji M; Nishimura H; Takatsu K; Shirai T; Hirose S Eur J Immunol; 2004 Oct; 34(10):2740-9. PubMed ID: 15368290 [TBL] [Abstract][Full Text] [Related]
14. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice. Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074 [TBL] [Abstract][Full Text] [Related]
15. Genetic and cellular basis of anti-DNA antibody synthesis in systemic lupus erythematosus of New Zealand mice. Shirai T; Hirose S; Sekigawa I; Okada T; Sato H J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():11-20. PubMed ID: 3497267 [TBL] [Abstract][Full Text] [Related]
16. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Perrotta S; Locatelli F; La Manna A; Cennamo L; De Stefano P; Nobili B Br J Haematol; 2002 Feb; 116(2):465-7. PubMed ID: 11841453 [TBL] [Abstract][Full Text] [Related]
17. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115 [TBL] [Abstract][Full Text] [Related]
18. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950 [TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization. Wu GD; He Y; Chai NN; Toyoda M; Dunn R; Kehry MR; Klein AS; Jordan SC Transpl Immunol; 2008 Jul; 19(3-4):178-86. PubMed ID: 18595710 [TBL] [Abstract][Full Text] [Related]
20. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus. Goldblatt F; Isenberg DA Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]